A phase 1, open-label study to assess the absorption, metabolism, and excretion, including the mass balance, of a single oral dose of [14C]-etrumadenant in healthy male subjects
- Conditions
- Cancer, tumorsCancertumors
- Registration Number
- NL-OMON51599
- Lead Sponsor
- Arcus Biosciences, Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 8
1. Sex at birth : male.
2. Age : 18 to 55 years, inclusive, at screening.
3. Body mass index (BMI) : 18.0 to 32.0 kg/m2, inclusive, at screening.
4. Body weight : >=50 kg, inclusive, at screening.
5. Status : healthy subjects.
Further criteria apply, see protocol.
1. Employee of PRA or the Sponsor.
2. History of relevant drug and/or food allergies.
3. Using tobacco products within 2 months prior to drug administration.
4. History of alcohol abuse or drug addiction (including soft drugs like
cannabis products) over the past 2 years.
5. Positive drug and alcohol screen (opiates, methadone, cocaine, amphetamines
[including ecstasy], cannabinoids, barbiturates, benzodiazepines, tricyclic
antidepressants, and alcohol) at screening or (first) admission to the clinical
research center.
Further criteria apply, see protocol.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method